ArticleMolecules (Basel, Switzerland)2018
Novel Guanidine Compound against Multidrug-Resistant Cystic Fibrosis-Associated Bacterial Species.
Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 46 citations in OpenAlex.
- Novel Thiourea Ligands-Synthesis, Characterization and Preliminary Study on Their Coordination Abilities.Molecules (Basel, Switzerland) · 2024Article
- Development of Novel Membrane Disrupting Lipoguanidine Compounds Sensitizing Gram-Negative Bacteria to Antibiotics.ACS medicinal chemistry letters · 2024Article
- Antibacterial activity of isopropoxy benzene guanidine againstFrontiers in pharmacology · 2024Article
- Mechanism of Action of Isopropoxy Benzene Guanidine against Multidrug-Resistant Pathogens.Microbiology spectrum · 2023Article
- Recent trends in chemistry, structure, and various applications of 1-acyl-3-substituted thioureas: a detailed review.RSC advances · 2022Review
- Anti-Biofilm Coatings Based on Chitosan and Lysozyme Functionalized Magnetite Nanoparticles.Antibiotics (Basel, Switzerland) · 2021Article
- Synthesis, Antibacterial and Antifungal Activity of New 3-Aryl-5Molecules (Basel, Switzerland) · 2021Article
- Development of a Promising Method for Producing Oligomeric Mixture of Branched Alkylene Guanidines to Improve Substance Quality and Evaluate Their Antiviral Activity against SARS-CoV-2.Molecules (Basel, Switzerland) · 2021Article
- EGCG-Mediated Potential Inhibition of Biofilm Development and Quorum Sensing inInternational journal of molecular sciences · 2021Article
- Indole Derivatives Obtained from EgyptianAntibiotics (Basel, Switzerland) · 2021Article
- In Vitro and In Vivo Evaluation of the Toxic Effects of Dodecylguanidine Hydrochloride.Toxics · 2020Article
- Is Only Clarithromycin Susceptibility Important for the Successful Eradication ofAntibiotics (Basel, Switzerland) · 2020Article
- Secondary Antibiotic Resistance, Correlation between Genotypic and Phenotypic Methods and Treatment inAntibiotics (Basel, Switzerland) · 2020Article
- Discovery of a Novel Mutation in DNA Gyrase and Changes in the Fluoroquinolone Resistance ofAntibiotics (Basel, Switzerland) · 2020Article
- Genomic Analysis of CarbapenemaseMicroorganisms · 2020Article
- Nursing Students' Knowledge and Awareness of Antibiotic Use, Resistance and Stewardship: A Descriptive Cross-Sectional Study.Antibiotics (Basel, Switzerland) · 2019Article
- Carbapenemase Genes and Multidrug Resistance ofAntibiotics (Basel, Switzerland) · 2019Article
- Novel C-2 Symmetric Molecules as α-Glucosidase and α-Amylase Inhibitors: Design, Synthesis, Kinetic Evaluation, Molecular Docking and Pharmacokinetics.Molecules (Basel, Switzerland) · 2019Article
- A novel mechanism of action of ketoconazole: inhibition of theInfection and drug resistance · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pulmonary infection is a hallmark of lung disease in cystic fibrosis (CF). Infections dominated by non-fermentative Gram-negative bacilli are particularly difficult to treat and highlight an urgent need for the development of new class of agents to combat these infections. In this work, a small library comprising thiourea and guanidine derivatives with low molecular weight was designed; these derivatives were studied as antimicrobial agents against Gram-positive, Gram-negative, and a panel of drug-resistant clinical isolates recovered from patients with CF. One novel compound, a guanidine derivative bearing adamantane-1-carbonyl and 2-bromo-4,6-difluouro-phenyl substituents (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.